Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-AML-901 in newly diagnosed acute myeloid leukaemia
ISRCTN12537955Phase 2Not yet recruiting
- Sponsor
- DIDACT Foundation
- Start
- Nov 2026
- Modality
- Small Molecules, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of tagraxofusp, venetoclax, cytarabine and cladribine in acute myeloid leukemia (AML), sponsored by DIDACT Foundation. Primary endpoint: Event-free survival. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
tagraxofuspvenetoclaxcytarabinecladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ISRCTN12537955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12537955.